Injectable semaglutide versus oral semaglutide in obesity management: a 68-week prospective comparative study

作者
Antaryami Sahoo
出处
期刊:Medical Research Journal [VM Media Sp zo.o. - VMGroup SK]
卷期号:11 被引量:1
标识
DOI:10.5603/mrj.112993
摘要

Introduction. Semaglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist for obesity, but direct comparative evidence between weekly injectable and high-dose oral formulations remains limited. This study compared the effectiveness, tolerability, and adherence of injectable semaglutide 2.4 mg once weekly versus oral semaglutide 50 mg once daily in adults with obesity. Material and methods. In this prospective, open-label, real-world comparative effectiveness study, 240 adults with BMI ≥ 30 kg/m² or BMI ≥ 27 kg/m² with an obesity-related comorbidity received injectable semaglutide or oral semaglutide according to nonrandomized allocation based on routine clinical decision-making and patient treatment preference, both with structured lifestyle intervention, for 68 weeks. The primary endpoint was percentage body-weight change from baseline to week 68. Secondary endpoints included categorical weight-loss responses, BMI, waist circumference, HbA1c, systolic blood pressure, adherence, and adverse events. Results. Mean percentage weight loss was greater with injectable semaglutide than with oral semaglutide (−14.7 ± 4.9% vs. −13.3 ± 5.7%; adjusted between-group difference, −1.4 percentage points (95% CI −2.7 to −0.1); p = 0.033). Weight loss ≥ 15% occurred in 47.5% vs. 33.3% and weight loss ≥ 20% in 15.8% vs. 12.5%, respectively. Both groups showed clinically meaningful reductions in BMI, waist circumference, HbA1c, and systolic blood pressure. Gastrointestinal adverse events were common but generally mild; adherence was higher with weekly injectable therapy. Conclusions. In this prospective comparative effectiveness study, injectable semaglutide produced modestly greater weight reduction and adherence, whereas oral semaglutide remained a clinically effective noninjectable option. Route preference, adherence capacity, tolerability, and availability should guide individualized obesity pharmacotherapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xionghaizi完成签到,获得积分10
刚刚
2ilo_完成签到,获得积分10
刚刚
Tatum完成签到,获得积分10
1秒前
Dilmma完成签到,获得积分10
1秒前
专注科研的昕昕鼠完成签到 ,获得积分10
2秒前
欢喜的笑白完成签到 ,获得积分10
2秒前
小曹医生完成签到,获得积分10
2秒前
胖墩儿驾到完成签到,获得积分10
3秒前
zhf发布了新的文献求助10
3秒前
思茶念酒完成签到 ,获得积分10
3秒前
jeery完成签到 ,获得积分10
3秒前
WJane完成签到,获得积分10
4秒前
Ballyhooed完成签到,获得积分10
4秒前
热心市民小红花的应助被hyyyg采纳,获得10
4秒前
有心事的风景完成签到,获得积分10
4秒前
隐形曼青的应助被wang采纳,获得10
5秒前
5秒前
卷王完成签到,获得积分10
5秒前
liu发布了新的文献求助10
5秒前
foyefeng完成签到,获得积分10
6秒前
番茄完成签到,获得积分10
6秒前
天天快乐的应助被简隋英采纳,获得10
6秒前
jiabu完成签到,获得积分10
6秒前
az完成签到,获得积分20
6秒前
ccx完成签到,获得积分10
7秒前
8秒前
今后的应助被有心事的风景采纳,获得10
8秒前
8秒前
又见白龙完成签到,获得积分10
9秒前
ZM完成签到,获得积分10
9秒前
zc完成签到,获得积分20
10秒前
眼睛大初翠完成签到,获得积分10
10秒前
10秒前
11秒前
淡如水完成签到,获得积分10
11秒前
清风完成签到,获得积分10
11秒前
Snowy完成签到,获得积分10
12秒前
huo关闭了huo的文献求助
13秒前
奋斗发布了新的文献求助10
14秒前
梁晓雪完成签到 ,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159174
求助须知:如何正确求助?哪些是违规求助? 9554642
关于积分的说明 21720253
捐赠科研通 7748830
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552091
邀请新用户注册赠送积分活动 2471464